Here are some highlights from last week's earnings coverage from BloggingStocks:

• Alcoa Inc. (NYSE: AA) reported a surprise Q3 profit due to cost cutting; revenue topped estimates as well.
• Avis Budget Group Inc. (NYSE: CAR) said a proposed offering of $250 million in notes could reduce earnings.
• Clorox Co. (NYSE: CLX) earnings prospects garnered it an upgrade from one analyst.
• Coca-Cola Co. (NYSE: KO) earnings prospects resulted in an upgrade from one analyst.
• Costco Wholesale Corp. (NASDAQ: COST) lower Q4 earnings topped analysts' expectations, lifting shares.
• Family Dollar Stores Inc. (NYSE: FDO) higher Q4 earnings beat analysts' estimates but sales were just OK.

Analyst upgrades:

• Deutsche Bank upgraded Coca-Cola (NYSE: KO) to Buy from Hold on expectations that stable volumes and a better outlook for currency and commodities will lead to higher earnings visibility. The firm raised its price target on shares to $62 from $52.
• FBR Capital upgraded Goodrich (NYSE: GR) to Outperform from Market Perform as it finds the stock's valuation compelling following the recent pullback. The firm raised its target on shares to $65 from $46.
• William Blair upgraded Cisco (NASDAQ: CSCO) to Outperform from Market Perform after channel checks indicated demand is accelerating as the firm finds the stock's valuation compelling at current levels.
• Robbins & Myers (NYSE: RBN) was upgraded to Outperform from Neutral at Baird.
• Disney (NYSE: DIS) and Viacom B (NYSE: VIA.B) were upgraded to Neutral from Underperform at BofA/Merrill, while News Corp. (NASDAQ: NWS) was upgraded to Buy from Neutral.

TheStreet.com's Jim Cramer says picking stocks -- or worse, picking a bottom -- remains a dangerous activity.

Sometimes it is so bad that it is BAD! Don't laugh at that seeming bit of counterintuitive logic. Every investment professional knows that because of the way economic cycles and central banks work, you are often looking for signs of such stress and negativity that it is so bad it is GOOD because of what the banks can do and what a bottom looks like.

This time it hasn't worked out that way. This time, what's bad is bad and getting worse. This weekend, David Carr in The New York Times wrote an excellent piece about the mistake of looking for a silver lining, something that news media does.

Analyst upgrades:

• Barclays upgraded Best Buy (NYSE:BBY) to Overweight from Equal Weight and raised their target to $35 from $28 citing the company's earnings power and free cash flow generation.
  
• William Blair upgraded St. Jude Medical (NYSE:STJ) to Outperform from Market Perform following the company's Q4 results on valuation and the company's "steady growth."
  
• Wunderlich upgraded Liberty Interactive (NASDAQ:LINTA) to Buy from Hold as they believe debt concerns are overdone. The firm thinks that language in the proxy statement for the Liberty Entertainment hard spin suggests that cash and cash flow from the stub Entertainment tracker could be used to provide inter-company support to Interactive. The firm raised their target to $5 from $4.25.
• Lloyds TSB Group (NYSE:LYG) was raised to Buy from Hold at Citigroup.
  
• BB&T (NYSE:BBT) was removed from Goldman's Conviction Sell List.
  
• Patni Computer (NYSE:PTI) was upgraded to Buy from Hold at KeyBanc.

This post is part of a series featuring bargain stocks that are worth a look now. See more Cheap Stocks.

You've probably heard that heart disease is one of the leading causes of death in the U.S. I don't mean to be a total downer in bringing up this bit of trivia; in fact, the prevalence of cardiac-related illnesses is actually a boon for Minnesota-based St. Jude Medical (NYSE: STJ). The company is engaged in the design, manufacture, and distribution of various cardiovascular medical devices, including pacemakers, replacement valves, and many more.

In mid-October, St. Jude reported higher-than-expected third-quarter sales. The medical-device firm also tightened up its full-year outlook, primarily due to the effects of currency fluctuations. However, Chief Financial Officer John Heinmiller said STJ is "confident" it can meet or exceed Wall Street's 2009 earnings estimates.

St. Jude also believes it's well-insulated from macroeconomic turmoil. CEO Daniel Starks observed that his company's products address "key health concerns," which means they're hardly discretionary items. "We expect very minimal impact from the broader and economic dynamics, and think we're in a good defensive position that way," Stark noted.

Analyst upgrades:

• UBS upgraded Pacific Sunwear (NASDAQ: PSUN) to Neutral from Sell and said liquidity is no longer a near-term concern. The firm lowered Pacific Sunwear's target to $1.50 from $3. Citigroup upgraded shares to Hold from Sell on valuation following the recent weakness and believes Pacific Sunwear has sufficient liquidity to remain a going concern.
  
• Calyon believes Reliant Energy (NYSE: RRI) will be successful in unwinding the Merrill Lynch Retail credit sleeve and obtaining alternative collateral. The firm upgraded shares to Buy from Add.
  
• JP Morgan said Cogent's (NASDAQ: COGT) position in homeland security and the defense markets make it less sensitive to an economic downturn, making valuation attractive. JP Morgan upgraded shares to Overweight from Neutral and raised its target to $13 from $10.50.
• Goldman added Research in Motion (NASDAQ: RIMM) to its Conviction Buy List and removed Riverbed (NASDAQ: RVBD) from the Conviction Sell List.
  
• J.M. Smucker (NYSE: SJM) was raised to Buy from Underperform at Merrill Lynch.

St. Jude Medical (NYSE: STJ) designs, manufactures, and distributes medical devices for heart-related and neurological conditions. The firm's Cardiac Rhythm Management segment makes pacemakers and implantable cardioverter defibrillators, to regulate heart rhythm. The Neuromodulation unit develops pacemaker-like implantable systems to treat chronic, intractable pain, and other nervous system disorders. The Cardiovascular division offers therapies and technologies for treating people with cardiovascular and peripheral vascular disease. The Atrial Fibrillation segment develops products to diagnose, treat, and seek a cure for atrial fibrillation. Boston Scientific (NYSE: BSX) is a major competitor.

The company pleased investors last week, when it reported Q2 EPS of 60 cents and revenues of $1.14 billion. Analysts had been expecting 55 cents and $1.06 billion. The CEO noted that revenue exceeded guidance in every business category. Management also guided Q3 EPS to 56-58 cents (53 cent consensus) and FY08 EPS to $2.28-$2.33 ($2.19 consensus).

MOST NOTEWORTHY: Pericom, St. Jude Medical and CDC Corp were today's noteworthy initiations:

• B. Riley believes Pericom (NASDAQ: PSEM) is in the early stages of a product cycle-driven growth and feels shares are significantly undervalued at current levels. The firm started shares with a Buy rating and $18 target.
  
• Rodman & Renshaw started St. Jude Medical (NYSE: STJ) with a Market Outperform rating and $50 target. The firm is positive on St. Jude's recent investments in its CRM product portfolio and sales organization, which should increase competitiveness and facilitates continued market share gains.
  
• CDC Corp (NASDAQ: CHINA) was initiated at Cantor with a Buy rating and $6 target, as they believe the stock is significantly undervalued due to the complexity of the company's corporate structure and poor financial disclosure. The firm believes this gap will close after the company lists at least one of its subsidiaries this year.

OTHER INITIATIONS:

• Kevin Dann initiated Orion Marine Group (NASDAQ: OMGI) with a Buy rating and $18 target.
  
• JP Morgan initiated Chimera Investment (NYSE: CIM) with a Neutral rating.
  
• Credit Suisse started Perrigo Company (NASDAQ: PRGO) with a Neutral rating and $40 target.

MOST NOTEWORTHY: CTC Media, Callidus Software and Seattle Genetics were today's noteworthy initiations:

• Merrill initiated CTC Media (NASDAQ: CTCM) with a Buy rating, citing the company's healthy ad growth outlook and substantial barriers to entry.
  
• B. Riley initiated Callidus Software (NASDAQ: CALD) with a Buy rating and $7 target and believes the company's growing On-Demand offering is being overlooked by investors.
• Seattle Genetics (NASDAQ: SGEN) was assumed with an Overweight rating at JP Morgan. The firm views the company as an attractive investment opportunity given the company's growing pipeline of differentiated antibody therapies and partnership with Genentech (NYSE: DNA).

OTHER INITIATIONS:

• Cowen initiated Boston Scientific (NYSE: BSX) with a Neutral rating and St. Jude Medical (NYSE: STJ) with an Outperform rating.
  
• Lehman initiated UDR Inc (NYSE: UDR) with an Equal Weight rating.

As the U.S. baby boom generation ages, demand for medical services is likely to increase, which is good news for St. Jude Medical.

St. Jude Medical (NYSE: STJ) develops and markets devices that treat cardiovascular disease and is also one of the world's leading manufacturers of mechanical heart valves.

St. Jude Medical's core business is its cardiac rhythm management division, which includes pacemakers, implantable cardioverter defibrillators [ICDs] and other equipment to regulate heart rhythm.

In general, analysts believe new product introductions and enhancements to existing products will allow STJ to increase its ICD market share in 2008, with overall company revenues advancing 13-17%. The Reuters F2007/F2008 EPS consensus estimates for STJ are $1.80/$2.09.

The risks? Analysts are keeping an eye on STJ's new product roll-out timetable. Further, negative changes to Medicare reimbursement rates would also hurt STJ's results.

The First Call mean rating for STJ is: Buy [25 firms]. Mean 2008 target: $47.00 [high: $54, low: $40].

Stock Analysis: St Jude Medical is a moderate-risk stock not suitable for low-risk investors. Investors with an investment horizon longer than two years should be rewarded from STJ's shares. Sell / Stop Loss if you were to purchase shares in this company: $28.

MOST NOTEWORTHY: News Corp, Limelight Networks, Corning and Carmike Cinemas were today's noteworthy initiations:

• RBC Capital is positive on News Corporation's (NYSE: NWS) strategy of investing cash flow away from mature enterprises to fund high-growth initiatives such as Sky Italia and Fox Interactive Media. The firm initiated shares with an Outperform rating and $26 target.
  
• Kaufman Brothers rates Limelight Networks Inc (NASDAQ: LLNW) a Sell based on a significant increase in the competitive environment with Akamai discounting on large deals, Level 3 Communications Inc (NASDAQ: LVLT) introducing a competitive offering in November 2007, Korean major-CD Networks becoming aggressive, and new entrants becoming aggressive with their value propositions.
  
• Deutsche Bank initiated Corning Inc (NYSE: GLW) with a Buy rating and $31 target as they believe shares are fundamentally undervalued given the company's strong fundamentals and promising outlook.
  
• Carmike Cinemas Inc (NASDAQ: CKEC) was started at JP Morgan with an Overweight rating. The firm said the company is the most exposed to 3-D, which could lead to potential upside due to low margins and leverage capital structure.

OTHER INITIATIONS:

• UBS started shares of St. Jude Medical Inc (NYSE: STJ) with a Sell rating and $43 target and shares of Medtronic Inc (NYSE: MDT) with a Buy rating and $64 target.
  
• Bear Stearns initiated shares of TJX Companies Inc (NYSE: TJX) and Ross Stores Inc (NASDAQ: ROST) with Peer Perform ratings.
  
• KeyBanc initiated shares of LaSalle Hotel Properties (NYSE: LHO) with a Hold rating.
  
• Caris started shares of Acme Packet Inc (NASDAQ: APKT) with an Above Average rating and $17 target.

MOST NOTEWORTHY: Boston Scientific (BSX), Medtronic (MDT), St. Jude Medical (STJ), Bankrate (RATE) and AXA (AXA) were today's noteworthy initiations:

• Thomas Wiesel initiated coverage of the Medical Devices Industry:
• Boston Scientific (NYSE: BSX) was initiated with an Underweight rating, expecting shares to Underperform peers due to reductions in estimates, risks to the stent business and valuation.
  
• Medtronic (NYSE: MDT) was initiated with an Overweight rating, saying attractively valued as they believe the growth in underlying markets may be more robust than the current sentiment suggests.
  
• St. Jude Medical (NYSE: SJT) was initiated with an Overweight rating, saying shares offer exposure to attractive drivers, a management team with the best track record in the segment, and a potential acquisition candidate.
  

• Stephens believes the recent weakness in Bankrate (NASDAQ: RATE) due to "turmoil" in the market has created an attractive entry point, starting shares with an Overweight rating.

• Morgan Stanley assumed coverage of AXA (NYSE: AXA) with an Overweight rating, citing an attractive risk/reward and strong free cash flow...

OTHER INITIATIONS:

• S1 Corp (NASDAQ: SONE) was initiated with a Market Perform rating at Avondale.

• Needham started Blue Coat Systems (NASDAQ: BCSI) with a Buy rating.

• Credit Suisse initiated AK Steel (NYSE: AKS) with a Neutral rating.

• Jefferies started Molex (NASDAQ: MOLX) with a Hold rating.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

MOST NOTEWORTHY: MoneyGram (MGI), F5 Networks (FFIV), ARK Restaurants (ARKR), Nara Bancorp (NARA) and St. Jude Medical (STJ) were today's noteworthy initiations:

• AG Edwards initiated MoneyGram (NYSE: MGI) with a Buy rating because it believes the recent pullback in the shares provides an attractive entry point; Stephens started shares of MoneyGram with an Overweight rating, and believes the company is well positioned to create strong transactional growth and take market share.

• CIBC expects F5 Networks (NASDAQ: FFIV) to benefit from strong fundamentals in application networking solutions and started shares with a Sector Outperformer rating and $85 target.

• Morgan Joseph initiated ARK Restaurants (NASDAQ: ARKR) with a Buy rating and $43 target; they believe ARK is well positioned to benefit from strong SSS & earnings leverage given its strong store locations, wide ranging price points, and stable unit development pipeline.

• Sandler is positive on Nara Bancorp (NASDAQ: NARA), starting shares with a Buy rating and $17 target, based on the company's long-term prospects.

• ThinkEquity believes St. Jude Medical (NYSE: STJ) is poised to take market share in the ICD markets and started shares with a Buy rating and $56 target...

OTHER INITIATIONS:

• JP Morgan initiated Softbank (OTC: SFTBF) with an Underweight rating and Nippon Telegraph & Telephone (NYSE: NTT) with a Neutral rating.

• Goldman reinstated Bausch & Lomb (NYSE: BOL) with a Neutral rating.

• Banc of America initiated PharMerica (NYSE: PMC) with a Buy rating and $18 target.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Being a particularly hard-working organ, the heart can be subject to bouts of irregular behavior. A world leader in the development and application of technologies designed to keep the heart running smoothly is headquartered in St. Paul, Minnesota.

St. Jude Medical Inc. (NYSE: STJ) designs, manufactures, and distributes medical devices for heart-related and neurological conditions. The firm's Cardiac Rhythm Management segment makes pacemakers and implantable cardioverter defibrillators, to regulate heart rhythm. The Neuromodulation unit develops pacemaker-like implantable systems to treat chronic, intractable pain, and other nervous system disorders. The Cardiovascular division offers therapies and technologies for treating people with cardiovascular and peripheral vascular disease. The Atrial Fibrillation segment develops products to diagnose, treat, and seek a cure for atrial fibrillation. Boston Scientific (NYSE: BSX) is a major competitor.

The company pleased investors last week, when it reported Q2 EPS of 45 cents and revenues of $947 million. Analysts had been expecting 43 cents and $909.8 million. Management also guided Q3 EPS to 44-45 cents (45 cent consensus) and FY07 EPS to $1.74-$1.78 ($1.75 consensus). Wachovia subsequently upgraded the shares to "outperform" and Jefferies termed the valuation "attractive." The stock popped into a bullish "pennant" consolidation pattern on the news. Prices frequently exit pennants moving in the same direction they were traveling when they entered them. In this case, that would be to the upside.

Altogether, brokers now recommend the issue with four "strong buys," nine "buys," nine "holds" and one "sell." Analysts see a 17% average annual growth rate, through the next five years. The STJ Sales Growth rate (13.69%), EPS Growth rate (18.42%), Operating Margin (21.46%), Net Profit Margin (15.65%), Return on Assets (11.12%), Return on Investment (13.68%) and Return on Equity (21.82%) compare favorably with industry, sector and S&P 500 averages.

The stock is one of those used to calculate the S&P 500 Index. Institutional investors hold about 80% of the outstanding shares. Over the past 52 weeks, STJ has traded between $32.33 and $45.39. A stop-loss of $39.50 looks good here.

Larry Schutts is a contributing editor for Theflyonthewall.com and the Vice-President of Stockwinners.com.

MOST NOTEWORTHY: St. Jude Medical (STJ), Juniper Networks (JNPR), Satyam Computer (SAY), Clearwire (CLWR) and Citrix Systems (CTXS) were today's noteworthy upgrades:

• St. Jude Medical's (NYSE: STJ) upgrade to Outperform from Market Perform at Wachovia was based on signs of an ICD recovery and reasonable valuation.

• Baird upgraded shares of Juniper (NASDAQ: JNPR) to Outperform from Neutral following better-than-expected guidance; Goldman upgraded Juniper to Buy from Neutral.

• Satyam (NYSE: SAY) was upgraded to Positive from Neutral at Susquehanna citing better than expected growth.

• Clearwire (NASDAQ: CLWR) was upgraded to Outperform from Peer Perform at Bear Stearns following the announcement that Sprint (S) and Clearwire will form a Nationwide 4G/Wimax Network.

• Citrix (NASDAQ: CTXS) was upgraded at Jefferies to Buy from Hold as they believe the strong customer response to Presentation Server Platinum Edition and the pipeline buildup related to NetScaler 8.0 bode well for the second half of 2007...

OTHER UPGRADES:

• Lehman raised DSW Inc (NYSE: DSW) to Overweight from Equal-Weight.

• Goldman upgraded shares of Labor Ready (NYSE: LRW) to Neutral from Sell.

• Rodman upgraded shares of Encysive Pharma (NASDAQ: ENCY) to Market Perform from Underperform.

• Lazard upgraded Cubist Pharmaceuticals (NASDAQ: CBST) to Neutral from Sell.

• Selective Insurance (NASDAQ: SIGI) was upgraded at Fox Pitt to In Line from Underperform.

• Raymond James upgraded Pfizer (NYSE: PFE) to Strong Buy from Market Perform.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).